Balthaser Kevin bought ACRS
February 1, 2024 · Form 4 insider transaction
Balthaser Kevin bought 147,500 shares of Aclaris Therapeutics, Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 4 days after the transaction.
Direction
Acquired (buy-side)
Shares
147,500
Price
$0.00
Total value
N/A
InsiderBalthaser Kevin
RoleOfficer
SecurityRestricted Stock Units
Transaction codeA: Grant or award
Transaction dateFebruary 1, 2024
Filing dateFebruary 5, 2024
Shares owned after147,500
OwnershipDirect
10b5-1 planNo
AmendedNo
Footnotes
Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.; 50% of the shares underlying these restricted stock units vest on each of December 31, 2024 and December 31, 2025, subject to the Continuous Service (as defined in the Plan) of the Reporting Person as of each such date.